Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$236.34 USD
-5.84 (-2.41%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $236.50 +0.16 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.34 USD
-5.84 (-2.41%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $236.50 +0.16 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Q1 Earnings Scorecard and Analyst Reports for Exxon, Oracle & Eli Lilly
by Sheraz Mian
In addition to the Q1 earnings scorecard, today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Oracle (ORCL) and Eli Lilly (LLY).
BD (BDX) Receives EUA for New Coronavirus Detection Test
by Zacks Equity Research
Becton, Dickinson (BDX) receives EUA from the FDA for another molecular diagnostic test for COVID-19, which can return results in two to three hours.
Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress
by Sweta Jaiswal, FRM
It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.
BD Gets EUA for New Test to Combat the Coronavirus Crisis
by Zacks Equity Research
BD (BDX) partners with BioGX to introduce a new diagnostic test to help hospitals boost the capacity of quick, on-site testing of COVID-19.
BD Launches New Test to Help Combat the Coronavirus Outbreak
by Zacks Equity Research
BD (BDX), along with BioMedomics, launches a new point-of-care test to help fight the coronavirus outbreak.
Luminex (LMNX) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its NxTAG CoV Extended Panel that will be used to detect the SARS-CoV-2 virus.
Coronavirus Hits Elective Procedures: 3 MedTech Stocks to Avoid
by Trina Mukherjee
Amid the pandemonium on the account of coronavirus, we look into three stocks that have been struggling to cope with the scenario.
PerkinElmer (PKI) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
PerkinElmer (PKI) introduces test for the detection of coronavirus after it receives EUA for the same.
OPKO's BioReference Laboratories Widens COVID-19 Testing (Revised)
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
OPKO's BioReference Laboratories Offers COVID-19 Testing (Revised)
by Zacks Equity Research
OPKO's (OPK) BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties in New Jersey.
OPKO's BioReference Laboratories Widens COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
PRA Health's New Program to Lend Support to Healthcare System
by Zacks Equity Research
PRA Health's (PRAH) COVID-19 Monitoring Program will allow individuals to connect with a healthcare professional remotely while maintaining social distancing.
OPKO's BioReference Laboratories Offers COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties in New Jersey.
The Zacks Analyst Blog Highlights: Roche, Thermo Fisher Scientific, Becton, Dickinson and Teladoc Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Thermo Fisher Scientific, Becton, Dickinson and Teladoc Health
4 Potential Gainers Amid Intensifying Coronavirus Fears
by Trina Mukherjee
Amid the pandemonium associated with coronavirus, we look into four stocks that have the potential to benefit from this outbreak.
BD (BDX) & BioGX Submit EUA to Speed Up Coronavirus Screening
by Zacks Equity Research
BD (BDX) expects screening to ramp up by 1,000 per day once authorized.
BD MAX Gets CE Mark for Coronavirus Detection, Shares Up
by Zacks Equity Research
BD (BDX) and Spain's CerTest Biotec collaborate to detect the COVID-19 in Europe.
Coronavirus-Affected MedTech Drags S&P 500 Index Down
by Trina Mukherjee
Amid uncertainty surrounding the coronavirus outbreak, here are a few S&P 500 MedTech stocks that took a hit.
Becton Dickinson (BDX) Down 5.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 MedTech Stocks to Rebound After Coronavirus-Led Recoil
by Sriparna Ghosal
As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.
PDCO or BDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. BDX: Which Stock Is the Better Value Option?
Coronavirus Spreads Rapidly Worldwide: Medtech Stocks in Focus
by Aparajita Dutta
The coronavirus outbreak disrupts manufacturing and supply chain in China, which in turn might have taken a toll on U.S. Medtech stocks.
Bleak Outlook for Medical Dental Supplies Industry
by Sreyoshi Mukherjee
Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.
New Strong Sell Stocks for February 13th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.